Live feed19:00:00·2dPRReleasevia QuantisnowPinetree Therapeutics Announces Exercise of Option to License EGFR Degrader Program by AstraZenecaByQuantisnow·Wall Street's wire, on your screen.AZN· AstraZeneca PLCHealth Care